Load up this thin float disruptive anti-cancer play. Accumulating and see huge upside potential in ST/NT & LT. | Fearlessly buying this Nasdaq listed CANCER play on dips to sell someday at much higher prices as I see spike to $5 - $25 with vision & PAYtience. Stock has tendency to suddenly liftoff like 🚀. Anti CANCER Disruptive with huge growth potential as it keeps winning approvals and penetration in major markets globally. IceCure has developed minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal. It offers US FDA approved miniminally invasive cyroblation procedure that serves as an attractive alternative to traditional lumpectomy/surgery for Breast Cancer battling elderly women. Company reported 45% higher sales in 1st half of this year on YoY basis. Current mkt cap - $6 mln. Cash on hand - $12 mln (June end). Equity float: 2.52 mln shares. Outstanding: 4.64 mln shares. Company is transitioning from clinical validation